Modern transarterial chemoembolization as a step towards the treatment of malignanttumors of the uteri and cervix

Introduction: Advanced cases of carcinomas with parametrial and fornix infiltration often cause massive genital bleeding, with severe anemia, fast deterioration, and a high risk of death for patients. One method of stoped bleeding is transarterial chemoembolization, which has been studied. Methods: Seven women with advanced uterine and cervix cancer or the pelvic locoregional recurrence withgenital massive bleeding were treated using an endovascular therapy (transarterial chemoembolization (TACE) using cisplatin or doxorubicin or gemcitabine). Ware used HepaSphere (Bioshere Medical, France) filled with saturated 50 mg doxorubicin or 500 mg gemcitabine or 50 mg cisplatin. Results: On average, the total operative time for the procedure was 52 minutes. In all cases, the achieved control bleeding. By the 7th day were signs of reduction in tumor size, 1/3 of its original size. The maximum effect on the tumor size was achieved within 14-20 days. In 2 cases, chemoembolization performed twice at an interval of 21 to 28 days, due to a good picture of the ultrasound tumor vascularization. All operations are carried out under the I/V anesthesia and we had no adverse reactions or complications. Conclusions: Arterial chemoembolization dominant vessels tumor is a reliable method of stopping the genital bleeding at any time during of the planned treatment. It is to improve the quality of life of patients. Antitumor efficacy of drug has a lasting effect. The method is applicable as a minimally invasive, effective for treatment of cancer patients.